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ABSTRACT
Due to the progressive nature of type 2 diabetes
(T2D), the majority of patients require
increasing levels of therapy to achieve and
maintain good glycemic control. At present,
once patients become uncontrolled on oral
antidiabetic therapies, the two primary
treatment options are glucagon-like peptide-1
receptor agonists (GLP-1RAs) or basal insulin,
although earlier use of GLP-1RAs has also been
advocated. While both of these drug classes
have proven efficacy in treating T2D, there can
be limitations to their use in some patients, and
resistance to further treatment intensification
among both patients and physicians. More
recently, treatment incorporating both a GLP-
1RA and a basal insulin has been used
successfully in the clinic and the first such
combination product, IDegLira (insulin
degludec ? liraglutide), has recently been
approved for use in Europe. IDegLira combines
insulin degludec and the GLP-1RA liraglutide in
a single injection. In both insulin-naı¨ve and
basal insulin-treated individuals with T2D,
IDegLira has demonstrated greater reductions
in glycated hemoglobin (HbA1c) than either of
the individual components, with a low rate of
hypoglycemia and weight loss. IDegLira may
provide a new option for patients requiring
treatment intensification but for whom
increased weight or a higher risk of
hypoglycemia are barriers. This article
discusses the rationale behind combining
these two drug classes and reviews the
available clinical evidence for the efficacy and
safety of IDegLira.
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Diabetes mellitus is a growing global epidemic
with a serious impact on healthcare systems and
economic costs. In 2013, there were an
estimated 382 million people living with
diabetes worldwide and a total global
healthcare expenditure of US$548 billion
related to treating the disease [1]. Further,
diabetes prevalence is increasing, with the
number of people with diabetes predicted to
rise to 592 million by 2035 [1]. The incidence of
type 2 diabetes (T2D) in particular is on the
increase and expected to make up the majority
of new cases of diabetes diagnosed between now
and 2035 [1].
Current treatment of T2D focuses on
achieving tight glycemic control to minimize
long-term microvascular complications, namely
retinopathy, nephropathy, and neuropathy.
Tight glycemic control achieved with intensive
glucose-lowering treatment within the first
years after diagnosis reduces the risk of long-
term complications of diabetes, resulting in
improved quality of life for the patient and
decreased healthcare costs [2]. However, there is
a need to exercise judgment in determining
who should receive treatment aimed at
achieving stringent glycemic targets. In those
patients with coronary disease, renal failure and
advanced age, a more relaxed treatment target
may be more appropriate [2, 3].
In combination with fasting plasma glucose
(FPG) and postprandial glucose, measurement
of glycated hemoglobin (HbA1c) is the usual
method of diagnosing and clinically tracking
diabetes control. Current guidelines for the
treatment of T2D recommend that patients
should aim for glycemic targets ranging from
HbA1c\7.5% (National Institute for Health and
Care Excellence [NICE]) and\7.0% (American
Diabetes Association [ADA] and European
Association for the Study of Diabetes [EASD])
to B6.5% (American Association of Clinical
Endocrinologists [AACE]), with the need for
intensive versus more relaxed control based on
multiple factors such as age and the presence of
comorbidities [2, 4–6]. Unfortunately, a large
proportion of people with T2D globally are not
currently meeting these targets [7–9].
There are limitations to the use of HbA1c as a
diagnostic measure, particularly early in T2D
disease progression, as some studies have found
evidence of diabetic complications such as
proliferative retinopathy at HbA1c levels\6.5%
[10, 11]. Patients may be labeled as having
prediabetes if their HbA1c is \6.5% but they
have certain risk factors or comorbidities such
as obesity, dyslipidemia, or a family history of
diabetes. Unfortunately, there are currently no
pharmacological agents approved for the
management of prediabetes, and patients must
rely initially on lifestyle measure alone.
However, the AACE guidelines do list
metformin as a first-line drug in prediabetes,
but also allow glucagon-like peptide-1 (GLP-1)
receptor agonists (GLP-1RAs) as appropriate
therapy in these patients when diet and
exercise alone are not successful (although this
is currently off-label) [6].
Good glycemic control is further
complicated by the progressive nature of T2D.
The majority of patients will require continual
intensification of treatment as beta cell function
deteriorates and endogenous insulin
production declines [2]. The majority of
available antidiabetic therapies lack
sustainability of glycemic control, suggesting
further progressive beta cell deterioration
despite their use, and further necessitating
treatment intensification [2]. As such, early
identification of T2D, particularly in high-risk
individuals, may be justified, along with earlier
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Lewis is a 54-year-old hypertensive male
with a history of type 2 diabetes diagnosed
4 years ago. At diagnosis he was started on
metformin 1000 mg twice daily and his
glycated hemoglobin (HbA1c) decreased
from 8.6% to 7.8%. Glimepiride 2 mg daily
was then added and his HbA1c decreased
further to 7.3%. He has also noted
approximately 2–3 minor hypoglycemic
events since the addition of glimepiride.
He has never woken up in the middle of the
night either diaphoretic or tachycardic.
Over the subsequent 18 months, his
glimepiride was increased to 4 mg daily, he
gained an additional 5 pounds (2.25 kg) in
weight and his HbA1c increased to 7.5%. He
has been a smoker for the past 30 years and
has not had much success in stopping
smoking, despite using electronic
cigarettes, or nicotine patches or gum. He
also has hypertension and dyslipidemia,
managed with losartan 50 mg daily and
rosuvastatin 10 mg daily. His blood
pressure is currently 142/70 mmHg, his
body mass index is 32 kg/m2, and his low-
density lipoprotein cholesterol is 90 mg/dL
(2.3 mmol/L). He had a normal cardiac
stress test for evaluation of atypical chest
discomfort approximately 7 months ago.
He is now in your office and his point-
of-care HbA1c is 8.0%. What will be the
next step in treatment?
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by either of the authors.
CURRENT TREATMENT OPTIONS
The first line of treatment in T2D is lifestyle and
diet modification; in most instances, this is then
followed by initiation of treatment with
metformin if blood glucose levels remain
uncontrolled. Most guidelines then
recommend adding in further oral
antidiabetics (primarily a sulphonylurea [SU]
or thiazolidinedione), dipeptidyl peptidase-4
(DPP-4) inhibitors, GLP-1RAs, sodium–glucose
co-transporter 2 (SGLT-2) inhibitors or (last but
not least) insulin after 3 months if target HbA1c
is not achieved and depending on factors such
as the patients’ body mass index and relative
hypoglycemia risk [3]. In our hypothetical
patient (see ‘‘Hypothetical Clinical Case:
Background’’), the addition of an SU as add-on
to metformin resulted in minor hypoglycemia
and weight gain.
The AACE guidelines in particular emphasize
the need to minimize weight gain and risks of
hypoglycemia, and to stratify treatment
recommendations according to HbA1c after
failure of lifestyle modifications. In patients
with HbA1c \7.5% prior to initiation of
antidiabetic agents, metformin is
recommended as first-line therapy. However,
in patients with HbA1c C7.5% in conjunction
with metformin, either DPP-4 inhibitors, SGLT-
2 inhibitors, or GLP-1RAs are recommended as
therapy intensification. Preference is given to
GLP-1RAs because of their potent effect on
HbA1c and/or weight loss. In patients with
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HbA1c [9%, either dual or triple therapy or
immediate initiation of insulin is recommended
[6]. In all guidelines, initiation of basal insulin is
indicated if the patient fails to reach or
maintain glycemic targets on a combination of
two or more antidiabetic agents [3, 6].
There is increasing focus on the need to
individualize therapy and targets based on the
particular needs of the patient [3]. In particular,
there have been calls to consider earlier
initiation of GLP-1RAs (with further
intensification using basal insulin if required)
in the treatment pathway [3], with the
possibility that this might slow disease
progression and preserve some pancreatic
function in some patients. In support of this
approach are clinical data showing
improvements in measures of beta cell
function such as homeostasis model
assessment-B (HOMA B) and proinsulin-to-
insulin ratio with GLP-1RAs [12–14]. In
addition to consideration of beta cell function,
the risk of hypoglycemia should also be taken
into account. Specifically, in those at particular
risk of hypoglycemia, a GLP-1RA may be
preferable to an SU due to the glucose-
dependent action of the former versus the
glucose-independent insulin secretion caused
by the latter.
The choice between addition of a GLP-1RA
and immediate initiation of a basal insulin
depends on the degree of disease progression,
the level of glycemic control and other factors
such as the risk of weight gain, each of which
will be specific to each individual patient. The
two address different portions of the
pathophysiological deficits in T2D, and each
can safely and effectively help many patients to
achieve recommended glucose targets when
they are no longer able to do so with lifestyle
modification and oral antidiabetic drugs (OADs)
alone [15–19].
GLP-1 Receptor Agonists
GLP-1RAs have several benefits compared with
basal insulin therapy in people with T2D who
retain a level of endogenous insulin secretion.
Due to their glucose-dependent mechanism of
action, long-acting GLP-1RAs (e.g., liraglutide,
albiglutide, dulaglutide, exenatide extended
release) address both postprandial and fasting
blood glucose, in contrast to basal insulin,
which is designed to offer fasting blood
glucose control and inter-meal control only,
and short-acting GLP-1RAs such as exenatide
and lixisenatide, which offer more prandial
control and lower fasting control due to their
short half-life. The glucose-dependent action of
these agents also entails a lower risk of
hypoglycemia compared with basal insulin
[17, 18].
Additionally, it is well established that GLP-
1RAs encourage weight loss via extra-pancreatic
effects such as slowing gastric emptying and
reducing appetite at the level of the
hypothalamus, resulting in diminished energy
intake [17–20]. Weight loss of as much as 3 kg
over 52 weeks has been demonstrated with GLP-
1RAs, with liraglutide demonstrating the
greatest weight loss to date [21], while OADs,
particularly SUs and thiazolidinediones, show a
consistent tendency toward weight gain over
time [2, 22].
Across many clinical trials, the GLP-1RAs
have been shown to be effective in all stages of
diabetes. However, in those patients with little
to no beta cell function, initiation of basal
insulin is a necessary next step to reach and
maintain glycemic targets. Initiation of the
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After discussion about the potential
adverse events and side effects that can be
experienced, Lewis agrees to the addition of
liraglutide. He is started at a dose of 0.6 mg
daily for 1 week and, on week 2, titrates up
to 1.2 mg daily. During this titration phase,
glimepiride is discontinued. He complains
about early satiety and eating less. At one
point, he wanted to ‘‘get his money’s worth’’
from a meal so forced himself to finish his
meal. This precipitated some nausea
followed by vomiting. The symptoms went
away as time passed, and eventually he
titrated to a dose of 1.8 mg daily. He
managed to lose 12 pounds (5.4 kg) over
the course of 3 months, and his glycated
hemoglobin (HbA1c) decreased to 7.2%. He
has had hardly any hypoglycemic events;
however, he does note at times that his mid-
afternoon glucose is in excess of 200 mg/dL
(11.1 mmol/L). Intensification of his
therapy is discussed during this visit and
he commits to being more engaged in the
vigorous exercise program recommended, to
improve insulin sensitivity and assist in
weight loss.
Basal Insulin
The efficacy of basal insulin in T2D is well
established [4]. However, basal insulin has
traditionally been the final choice of treatment
in T2D, initiated only when the patient is
unable to maintain good glycemic control
after all previous options have been tried [3].
The newer basal insulin analogs, molecularly
designed to have specific pharmacokinetic
properties, have demonstrated significant
improvements over earlier insulins such as
neutral protamine Hagedorn (NPH) in terms of
day-to-day variability, effects on weight and
risks of hypoglycemia [23–27]. Improvements in
day-to-day variability of glucose-lowering effect
are of particular note as it has been shown that
greater fluctuation in FPG is linked to higher
levels of mortality [28]. Insulin detemir, insulin
glargine, and insulin degludec all demonstrate
decreased intra-patient variability compared
with NPH insulin [23, 29], while insulin
degludec has also shown decreased variability
compared with insulin glargine [23]. This
decreased variability leads to a more
predictable action and so a decreased risk of
hypoglycemia compared with insulin glargine
including a reduction of up to 36% in nocturnal
hypoglycemic events [27, 30].
Unfortunately, reluctance to initiate insulin
therapy persists even when patients fail to meet
glycemic targets on multiple OADs and there is
evidence that physicians continue to delay
initiation of basal insulin despite prolonged
HbA1c levels [31]. In one study of inertia,
patients on two OADs and with HbA1c [8%
experienced a mean delay of 26 months prior to
insulin initiation; in patients with HbA1c
between 7% and 8%, the delay was 51 months
[31]. In addition, many patients do not reach
glycemic targets (HbA1c B7.0%) with basal
insulin, either with a treat-to-target approach
in clinical trials [32–34] or in the general clinic
[35]. Initiation of basal insulin degludec is
described as ‘option 2’ for our hypothetical
patient.
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HYPOTHETICAL CLINICAL CASE
OPTION 2: ADDITION
OF A BASAL INSULIN ANALOG
Insulin degludec is initiated at a starting
dose of 10 units at bedtime. Lewis titrated by
3 units every 3 days using a self-titration
algorithm, and managed to reach a fasting
plasma glucose (FPG) target of
approximately 100 mg/dL (5.6 mmol/L).
His other medications remain the same. He
has suffered two minor nocturnal
hypoglycemic events over the past 2 weeks,
but it appears that his daytime control is a
little better. (Continuous glucose
monitoring data can be incorporated and it
is important to note that nocturnal
hypoglycemic events have occurred in
patients using basal insulin analogs with
near-normal glycated hemoglobin [HbA1c].)
Furthermore, the nocturnal hypoglycemic
events often went unnoticed. His HbA1c
today is 6.9%, but he has gained an
additional 6 pounds (2.7 kg).
CHALLENGES AND BARRIERS
TO INTENSIVE TREATMENT
Although the benefits of intensive therapy in
delaying the onset of diabetic complications
are well established, numerous studies have
shown that intensive glucose control,
particularly with agents such as insulin and
SUs, can result in an increased risk of
hypoglycemia and substantial weight gain [2,
36–38]. Fear of these negative side effects can
lead to both patients and physicians being
reluctant to intensify therapy, particularly with
insulin [39–41]. In addition, fear of and
experience of both hypoglycemia and weight
gain can negatively affect adherence to therapy
[40], which in turn has an impact on long-term
glycemic control [42]. The fear of and
experience of hypoglycemia may also lead to
de-escalation of insulin therapy in some
patients [43]. Conversely, there is some
evidence suggesting that patients who lose
weight on their diabetes therapy show better
treatment adherence than those who gain
weight during treatment [44].
Once basal insulin has been initiated, a
further barrier to intensification is the
increased number of injections and the
increased regimen complexity necessitated by
the addition of prandial insulin injections to
basal therapy [40, 41].
Because of the increased risks of
hypoglycemia and weight gain, and the
likelihood of decreased adherence as these
risks increase, treatment guidelines currently
recommend less stringent treatment, with
individualized targets and higher glycemic
targets in patients at particular risk of
hypoglycemia, of advanced age, with multiple
comorbidities and in those patients whose
adherence to treatment is lower [3].
While more recently introduced basal
insulin analogs demonstrate less variability
than NPH, leading to a reduced risk of
hypoglycemia [30] and a greater potential for
patients to confidently self-titrate [45], there is
still a pronounced fear of these side effects
among patients [39, 40]. Sometimes, primary
care physicians are also reluctant to prescribe
injectable therapies due to a lack of education
and/or the time-consuming nature of training
and follow-up of patients initiating insulin
therapy [40, 46]. Patient perception of failure
to control their diabetes, fear, embarrassment or
inconvenience of injection(s), and cost of
therapies are other potential barriers to insulin
initiation [40, 46, 47].
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GLP-1RAS AND BASAL INSULIN:
RATIONALE FOR A NEW
COMBINATION THERAPY
As outlined above, while the current options
available for post-OAD therapy in T2D have
proven efficacy, they are not ideal for all
patients. This is particularly the case for
patients who require more intensive treatment
to meet glycemic targets but who are at risk of
significant weight gain or hypoglycemia. Basal
insulins and GLP-1RAs have complementary
modes of action in the treatment of T2D. As
such, there is great interest in the potential use of
these agents in combination for some patients
who require greater reductions in HbA1c [48–51].
The feasibility of adding either a GLP-1RA to
basal insulin therapy or a basal insulin analog to
GLP-1RA therapy has been tested in several
trials in which a potential for greater HbA1c
reductions than with either therapy alone has
been demonstrated [52–54].
In one such trial, 988 participants
uncontrolled on metformin with or without
SU discontinued SU and started on liraglutide,
titrated up to 1.8 mg, for a 12-week run-in
period. At the end of this run-in period, those
who had not reached HbA1c \7% were
randomized to either add-on insulin detemir or
continue on liraglutide plus metformin for
26 weeks. Post-randomization, addition of
insulin detemir led to a further reduction in
HbA1c of 0.5% (from 7.6% at randomization)
compared with a 0.02% increase in HbA1c with
continued liraglutide plusmetformin alone [52].
In a study of liraglutide versus insulin aspart
as add-on to basal insulin degludec, addition of
liraglutide led to a significantly greater
reduction in HbA1c (-0.74%) at 26 weeks than
did once-daily prandial insulin aspart (-0.39%)
with a treatment difference of -0.32% (95% CI
-0.53 to -0.12, P = 0.0024) [53]. Further to this
improvement in HbA1c, significant reduction in
weight and a reduced risk of hypoglycemia was
demonstrated when compared with
intensification by addition of prandial insulin
to basal insulin therapy [53].
Due to the distinct, stable molecular forms of
both insulin degludec and liraglutide and their
complementary modes of action, IDegLira was
developed. Granted marketing authorization in
the European Union as of September 2014,
IDegLira is the first combination of a basal
insulin (insulin degludec) and a GLP-1 analog
(liraglutide) in one pen. Also under
development is a lixisenatide and insulin
glargine combination, although phase 3 trials
are still ongoing and, at present, limited clinical
data are available for this product.
IDegLira is a fixed ratio of insulin degludec
(100 U/mL) and liraglutide (3.6 mg/mL) with a
maximum dose of 50 Units IDeg/1.8 mg
liraglutide, corresponding with the maximum
approved dose of liraglutide, where the unit of
measure for this fixed-ratio combination will be
noted as ‘dosing steps’. The combination has
the potential to provide improved overall
glycemic control whilst mitigating some of the
common side effects experienced with GLP-
1RAs and basal insulin (e.g., nausea, weight
gain, and hypoglycemia).
IDEGLIRA: CLINICAL EVIDENCE
At present, published data are available for two
phase 3 clinical trials of IDegLira, one in insulin-
naı¨ve patients and one in patients previously
treated with basal insulin. Both were 26-week
(onewith a further 26-week extension phase [55])
randomized trials (2:1:1 and1:1, respectively), the
first (DUAL I; ClinicalTrials.gov number,
NCT01336023) being a treat-to-target, open-
label study comparing IDegLira with insulin
degludec or liraglutide alone in insulin-naı¨ve
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patients previously treated with metformin with
or without pioglitazone [55]. The second study
(DUAL II; ClinicalTrials.gov number,
NCT01392573) was a double-blind trial of
IDegLira compared with insulin degludec in
patients previously treated with basal insulin. As
part of the study design in DUAL II, the degludec
comparator armwas capped at 50 dose units. This
was so that the relative contribution of the
liraglutide component towards the overall
efficacy of IDegLira could be judged more
clearly, and was a regulatory requirement from
the US Food and Drug Administration [56].
In terms of efficacy in insulin-naı¨ve patients,
treatment with IDegLira produced a significantly
greater reduction in HbA1c (-1.9% from baseline)
than either degludec (-1.4% from baseline,
estimated treatment difference [ETD] -0.5%,
95% CI -0.6 to -0.4, P\0.0001) or liraglutide
(-1.3% frombaseline, ETD-0.6%, 95%CI-0.8 to
-0.5, P\0.0001) alone after 26 weeks [56]. In
addition, a significantly greater proportion of
patients achieved glycemic targets of HbA1c\7%
after 26 weeks of treatment with IDegLira than
with degludec (81% vs. 65%, P\0.0001) or
liraglutide (60%, P\0.0001) and HbA1c \6.5%
comparedwithdegludec (70%vs. 47%,P\0.0001)
or liraglutide (70% vs. 41%, P\0.0001).
This improvement in glycemic control
occurred in conjunction with a mean body
weight reduction of -0.5 kg with IDegLira,
compared with a weight increase of 1.6 kg with
degludec (P\0.0001 vs. IDegLira) and a weight
loss of 3.0 kg with liraglutide. In addition,
IDegLira also demonstrated a 32% lower rate of
hypoglycemia than degludec despite a lower
end-of-trial HbA1c (6.4% vs. 6.9% [46 mmol/mol
vs. 52 mmol/mol]). As would be expected due to
its mode of action, few subjects reported
hypoglycemia with liraglutide [55].
In those previously treated with basal
insulin, patients receiving IDegLira
experienced a significantly greater reduction in
HbA1c compared with those on degludec
(capped at 50 Units) after 26 weeks (-1.9% vs.
-0.9%, P\0.0001) [56]. At the 26-week
endpoint, 60% of participants in the IDegLira
group had achieved HbA1c\7% versus 23% in
the degludec arm (P\0.0001) and a
significantly higher proportion (40%) of
patients in the IDegLira arm achieved HbA1c
\7% with no confirmed hypoglycemic episodes
during the last 12 weeks of treatment and with
no weight gain, than in the degludec group
(8.5%, P\0.0001).
In this trial, patients receiving IDegLira
experienced a mean weight loss of 2.7 kg
compared with no weight change with
degludec. Confirmed hypoglycemia (including
severe events and defined as plasma glucose
\56 mg/dL [3.1 mmol/L] regardless of
symptoms, or if assistance required) was not
statistically significantly lower than for degludec
(1.5 events/patient-year vs. 2.6 events/patient-
year; P = not significant) with similar incidences
(IDegLira 24% vs. degludec 25%) and lower
HbA1c with IDegLira [56].
IDegLira was well tolerated in both trials, with
comparable levels of adverse events to the
individual treatment arms and low incidence of
severe adverse events [55, 56]. Overall, the
incidence of nausea was higher in the IDegLira
group than in the degludec group in both trials
(9% vs. 4% of patients in DUAL I; 6.5% vs. 3.5%
in DUAL II). However, in DUAL I, the incidence
of nausea was lower with IDegLira than with
liraglutide (9% vs. 20% patients). This reduced
level of nausea with IDegLira compared with
liraglutide is of particular interest and likely
stems from the more gradual increase in dose of
liraglutide when initiating and titrating IDegLira
compared with the standard liraglutide titration.
Overall, IDegLira offers simple titration of two
efficacious therapies in a single daily injection
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while mitigating the principal side effects of
basal insulin (hypoglycemia and weight gain)
and GLP-1RA (nausea) when given alone [55,
56]. Using a GLP-1RA and basal insulin together
in two separate injections can provide the greater
dosing flexibility that some patients may require
(such as those in need of high insulin doses), but
having both agents in one pen will offer greater
convenience/simplicity and may reduce patient
confusion. IDegLira will also offer a new weight-
neutral option for insulin initiation in patients
uncontrolled on OADs that has a lower risk of
hypoglycemia versus basal insulin initiation [55].
Initiation of IDegLira is described as ‘option 3’




Lewis agrees to initiation with IDegLira. He
is empowered with the up-titration algorithm
(decrease dose by two dose steps if fasting
plasma glucose [FPG]\72mg/dL [4 mmol/L],
no change in dose if FPG 72–90 mg/dL
[4–5 mmol/L], increase dose by two dose
steps if FPG [90 mg/dL [5 mmol/L]). He
starts with 10 dose steps (units of measure
for this fixed combination) and titrates every
week. By week 4, he achieves an FPG of
100 mg/dL (5.6 mmol/L). He has managed to
lose about 2 pounds, and has only suffered
one minor hypoglycemic reaction over the
previous month. He has noted that his post-
meal glucose never surpasses 150 mg/dL
(8.3 mmol/L). His point-of-care glycated
hemoglobin (HbA1c) is 6.8%. He is happy
with his progress, but you encourage him to
continue with his vigorous diet and exercise
program in addition to continuing with
IDegLira.
CONCLUSIONS
There are a number of treatment options
available for consideration when intensifying
treatment in patients with T2D, and there are
many factors to take into account when
deciding how to best achieve treatment goals.
Treatment should always be individualized to
most closely meet the needs and preferences of
the patient.
GLP-1RAs such as liraglutide demonstrate
postprandial glucose control as well as fasting
glucose control due to suppression of glucagon
release, both in a glucose-dependent fashion. In
contrast, basal insulins such as insulin degludec
have been shown to offer superior FPG control
as well as inter-meal control. IDegLira is the first
fixed-ratio combination of a basal insulin and
GLP-1 analog in a single injection and this
novel combination incorporates glucose-
dependent prandial control coupled with the
augmentation of fasting and inter-meal control
offered by insulin degludec. In clinical trials to
date, IDegLira has demonstrated improved
HbA1c in patients with T2D compared with
either liraglutide or insulin degludec alone, and
with a lower risk of hypoglycemia and weight
gain than insulin degludec alone. As such,
IDegLira offers another option for patients and
physicians who may be reluctant to initiate or
intensify insulin therapy due to concerns about
hypoglycemia and weight gain.
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